[go: up one dir, main page]

PT1351683E - Combinação compreendendo um antagonista do receptor at-1 e um estimulante da secreção de insulina ou um sensibilizador de insulina - Google Patents

Combinação compreendendo um antagonista do receptor at-1 e um estimulante da secreção de insulina ou um sensibilizador de insulina Download PDF

Info

Publication number
PT1351683E
PT1351683E PT01967289T PT01967289T PT1351683E PT 1351683 E PT1351683 E PT 1351683E PT 01967289 T PT01967289 T PT 01967289T PT 01967289 T PT01967289 T PT 01967289T PT 1351683 E PT1351683 E PT 1351683E
Authority
PT
Portugal
Prior art keywords
insulin
receptor antagonist
sensitizer
secretion stimulant
insulin secretion
Prior art date
Application number
PT01967289T
Other languages
English (en)
Inventor
Malcolm Allison
Marjorie Regan Gatlin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24581689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1351683(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT1351683E publication Critical patent/PT1351683E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT01967289T 2000-08-22 2001-08-20 Combinação compreendendo um antagonista do receptor at-1 e um estimulante da secreção de insulina ou um sensibilizador de insulina PT1351683E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64364100A 2000-08-22 2000-08-22

Publications (1)

Publication Number Publication Date
PT1351683E true PT1351683E (pt) 2008-09-18

Family

ID=24581689

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01967289T PT1351683E (pt) 2000-08-22 2001-08-20 Combinação compreendendo um antagonista do receptor at-1 e um estimulante da secreção de insulina ou um sensibilizador de insulina

Country Status (15)

Country Link
US (1) US20040034065A1 (pt)
EP (3) EP1980249A3 (pt)
JP (4) JP2004514654A (pt)
AR (1) AR033390A1 (pt)
AT (1) ATE399010T1 (pt)
AU (1) AU2001287698A1 (pt)
CL (1) CL2009001899A1 (pt)
CY (1) CY1111698T1 (pt)
DE (1) DE60134575D1 (pt)
DK (1) DK1351683T3 (pt)
MY (1) MY141012A (pt)
PE (1) PE20020617A1 (pt)
PT (1) PT1351683E (pt)
TW (3) TWI327468B (pt)
WO (1) WO2002015933A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
EP1483232A1 (en) * 2002-03-11 2004-12-08 Novartis AG Salts of nateglinide
KR100897890B1 (ko) 2002-06-17 2009-05-18 인벤티아 헬스케어 피브이티. 엘티디. 티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
ATE551056T1 (de) * 2002-12-27 2012-04-15 Takeda Pharmaceutical Mittel zur hemmung der körpergewichtszunahme
EP2517728B1 (en) * 2003-04-15 2015-01-28 Daiichi Sankyo Company, Limited Olmesartan medoxomil for preventing or treating angiogenic eye diseases
US20070054947A1 (en) * 2003-05-16 2007-03-08 Cohn Jay N Pharmaceutical composition comprising valsartan
WO2005092319A1 (en) * 2004-03-29 2005-10-06 Ranbaxy Laboratories Limited Rapidly disintegrating pharmaceutical compositions comprising nateglinide and a disintegrant
AU2005243214B2 (en) 2004-04-29 2011-07-07 U.S. Smokeless Tobacco Company Llc Nicotiana nucleic acid molecules and uses thereof
US7666899B2 (en) * 2004-05-11 2010-02-23 Kissei Pharmaceutical, Co. Ltd. Pharmaceutical composition for treatment of lipid metabolism disorder
US7588779B2 (en) * 2004-05-28 2009-09-15 Andrx Labs, Llc Pharmaceutical formulation containing a biguanide and an angiotensin antagonist
MX2007003716A (es) * 2004-10-07 2007-04-23 Takeda Pharmaceutical Agente para la profilaxis o tratamiento del sindrome metabolico.
JP2007099764A (ja) * 2005-09-09 2007-04-19 Ajinomoto Co Inc 血糖低下剤
WO2010122927A1 (ja) * 2009-04-20 2010-10-28 第一三共株式会社 糖尿病由来神経再生遅延の予防又は治療のための医薬
UA125535C2 (uk) * 2017-07-17 2022-04-13 Елі Ліллі Енд Компані Фармацевтичні композиції

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2951135A1 (de) 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
JPS6354321A (ja) 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
DK0955294T3 (da) 1989-06-14 2004-02-02 Smithkline Beecham Corp Imidazolylalkensyre
CA2073856C (en) 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
DE59107440D1 (de) 1990-02-19 1996-04-04 Ciba Geigy Ag Acylverbindungen
NZ237476A (en) 1990-03-20 1994-01-26 Sanofi Sa N-substituted heterocyclic compounds and pharmaceutical compositions.
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
SI9210098B (sl) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
AU654331B2 (en) 1991-03-30 1994-11-03 Kissei Pharmaceutical Co. Ltd. Succinic acid compounds
DK0965591T3 (da) 1991-06-21 2002-11-18 Boehringer Ingelheim Pharma Fremgangsmåde til fremstilling af (S)-3-methyl-1-(2-piperidino-phenyl)-1-butylamin
ATE149483T1 (de) 1991-07-30 1997-03-15 Ajinomoto Kk Kristalle von n-(trans-4- isopropylcyclohexylcarbonyl)-d-phenylalanin und verfahren zu ihrer herstellung
TW226375B (pt) 1991-10-24 1994-07-11 American Home Prod
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
SK117996A3 (en) * 1994-03-17 1997-03-05 Ciba Geigy Ag Pharmaceutical composition for treatment of diabetic nephropathy
AU696868B2 (en) * 1994-03-29 1998-09-17 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin II receptor blocking imidazoles
US5488510A (en) 1994-07-26 1996-01-30 Lemay; Edward J. Enhanced depth perception viewing device for television
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
SK283348B6 (sk) * 1996-04-05 2003-06-03 Takeda Chemical Industries, Ltd. Farmaceutický prípravok obsahujúci zlúčeninu s antagonickým účinkom na angiotenzín II
DE19616486C5 (de) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
JPH11315034A (ja) * 1998-03-04 1999-11-16 Takeda Chem Ind Ltd アンギオテンシンｉｉ拮抗作用を有する化合物の徐放性製剤、その製造法および用途
FR2778103A1 (fr) * 1998-04-29 1999-11-05 Sanofi Sa Compositions pharmaceutiques contenant en association un antagoniste v1a de l'arginine-vasopressine et un antagoniste des recepteurs at1 de l'angiotensine ii
CN1148361C (zh) * 1998-05-11 2004-05-05 武田药品工业株式会社 羟基亚氨基链烷酸衍生物
SK285863B6 (sk) * 1998-07-10 2007-10-04 Novartis Ag Kombinovaná farmaceutická kompozícia obsahujúca AT1-antagonistu valsartan a amlodipín
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
MXPA02001694A (es) * 1999-08-30 2002-08-06 Aventis Pharma Gmbh Uso de inhibidores del sistema renina-angiotensina en la prevencion de eventos cardiovasculares.
TW200514783A (en) * 1999-09-22 2005-05-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
AU6118001A (en) * 2000-05-03 2001-11-12 Tularik Inc Combination therapeutic compositions and methods of use
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US20020037829A1 (en) * 2000-08-23 2002-03-28 Aronson Peter S. Use of DPPIV inhibitors as diuretic and anti-hypertensive agents

Also Published As

Publication number Publication date
TWI327468B (en) 2010-07-21
CY1111698T1 (el) 2015-10-07
DK1351683T3 (da) 2008-10-20
TWI315197B (en) 2009-10-01
AR033390A1 (es) 2003-12-17
JP2010043101A (ja) 2010-02-25
WO2002015933A2 (en) 2002-02-28
ATE399010T1 (de) 2008-07-15
MY141012A (en) 2010-02-25
TW200843741A (en) 2008-11-16
JP2013049683A (ja) 2013-03-14
AU2001287698A1 (en) 2002-03-04
TWI327469B (en) 2010-07-21
US20040034065A1 (en) 2004-02-19
EP2138175A2 (en) 2009-12-30
WO2002015933A3 (en) 2003-08-14
EP1980249A2 (en) 2008-10-15
CL2009001899A1 (es) 2010-02-12
EP1351683A2 (en) 2003-10-15
TW200838503A (en) 2008-10-01
PE20020617A1 (es) 2002-08-05
EP1351683B1 (en) 2008-06-25
EP2138175A3 (en) 2010-01-13
JP2004514654A (ja) 2004-05-20
JP2015205909A (ja) 2015-11-19
DE60134575D1 (de) 2008-08-07
EP1980249A3 (en) 2010-04-28

Similar Documents

Publication Publication Date Title
PT1351683E (pt) Combinação compreendendo um antagonista do receptor at-1 e um estimulante da secreção de insulina ou um sensibilizador de insulina
BR0115124B1 (pt) dispositivo para fundir uma amostra hiperpolarizada sàlida, mÉtodo para produzir uma amostra hiperpolarizada fundida, e, uso de um dispositivo ou mÉtodo.
PT1177178E (pt) Benzimidazois hetereciclicos substituidos, sua preparacao e aplicacao
IS6779A (is) Mannlíkt mótefni gegn LT-beta-R
AU2002347022A1 (en) Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
BRPI0013439B8 (pt) composiÇço compreendendo tramadol e um fÁrmaco anticonvulsivante.
EE200300145A (et) Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon
PL367180A1 (pl) Trwała kompozycja farmaceutyczna
DE60138102D1 (de) Antikörper gegen menschliches mcp-1
ID29089A (id) Sediaan farmasi moksifloksasin
NO20032678L (no) NMDA reseptor agonist farmasöytiske sammensetninger
BRPI0208558A2 (pt) preparado de combinação de estrogênio-gestagênio e uso
ATE228500T1 (de) Npy antagonisten
DE69919171D1 (de) Muskarin-rezeptor antagonisten
EP1023437A4 (en) Receptor Kinase, BIN1
PT1237559E (pt) Combinacoes farmaceuticas compreendendo um antagonista do receptor p2t e megalatrano
BR0114661B1 (pt) conjunto de fixação de trilho ferroviário
BR0208566B1 (pt) Derivados de Beta-Carbolina, Seu Uso, e composição Farmacêutica
ATE374183T1 (de) Nk1-antagonisten
PT1146874E (pt) Antagonista de receptor da vitronectina
IT1318476B1 (it) Perno endocanalare per uso odontoiatrico e relativo metodo direalizzazione.
DE60100773D1 (de) Glycosphingolipid
NO20033223D0 (no) Histamin-reseptor antagonister
PT1448566E (pt) Antagonistas do receptor quimioquina e metodos de utilizacao do mesmo
FR2791084B3 (fr) Vantail de porte